Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

Abstract

INTRODUCTION Currently, no standard treatments are available for relapsed or refractory urothelial carcinoma (UC). Paclitaxel has demonstrated efficacy in the treatment of UC when used alone or combined with other cytotoxic therapies. We designed a phase II trial combining paclitaxel with pazopanib, a commonly used antiangiogenic agent with significant… (More)
DOI: 10.1016/j.clgc.2016.03.011

Topics

  • Presentations referencing similar topics